- Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
- Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
- Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank
- Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
- Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
- Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 49.70 |
---|---|
High | 49.90 |
Low | 49.10 |
Bid | 49.25 |
Offer | 49.30 |
Previous close | 49.80 |
Average volume | 3.87k |
---|---|
Shares outstanding | 23.12m |
Free float | 14.97m |
P/E (TTM) | -- |
Market cap | 1.15bn PLN |
EPS (TTM) | -4.05 PLN |
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼